Bertis Inc.
Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : contact@bertis.comIR : ir@bertis.comMedia : communication@bertis.com
BERTIS INC.
We are leading innovations in the quantitative
proteomics field by combining AI-driven research capabilities with a
library of proteomics data accumulated over 10 years.
AI Driven Proteomics Technology Company
Bertis
As members of the global proteomics
community,
Bertis Inc. is constantly seeking clinical innovations—empowered by AI and proteomics
technologies—that people around the world need to live healthier lives.
community,
Bertis Inc. is constantly seeking clinical innovations—empowered by AI and proteomics
technologies—that people around the world need to live healthier lives.
Bertis Inc. is leading the quantitative proteomics field based on a library of numerous data on quantified blood proteomes,
cells/tissues, and cancer cell-specific binding synthetic peptides.
Through the years of quantitative proteomics research combined with AI technology, we possess the technology and expertise
that have been successful in obtaining the Ministry of Food and Drug Safety(MFDS) approval and commercialization of “MASTOCHECK,”
the world’s first commercialized proteomics-based early breast cancer diagnostic solution.
cells/tissues, and cancer cell-specific binding synthetic peptides.
Through the years of quantitative proteomics research combined with AI technology, we possess the technology and expertise
that have been successful in obtaining the Ministry of Food and Drug Safety(MFDS) approval and commercialization of “MASTOCHECK,”
the world’s first commercialized proteomics-based early breast cancer diagnostic solution.
